Two of the greatest challenges in cell therapy development and driving new therapies toward commercial success are scalability and optimizing cost.
As the CEO of Precigen, a biopharmaceutical company dedicated to pursuing solutions for a range of intractable diseases through early discovery and clinical-stage research, Dr. Helen Sabzevari is ready to face these challenges. Dr. Sabzevari has spent years considering what it takes for rapid drug development and commercial viability in today’s market. Her previous work includes tenures in both academia and with EMD Serono, Compass Therapeutics, and Intrexon (now Precigen).
In a recent episode of The Business of Biotech, Dr. Sabzevari discussed how Precigen has used customized therapeutic and platform technologies to tackle scale-up in the CAR-T therapeutics space, helping patients and investors know they’re getting the most effective therapy at the best price.